| Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group. EJ Bastyr 3rd, CA Stuart, RG Brodows, S Schwartz, CJ Graf, A Zagar, ... Diabetes care 23 (9), 1236-1241, 2000 | 383 | 2000 |
| Metabolic and immunologic effects of insulin lispro in gestational diabetes. L Jovanovic, S Ilic, DJ Pettitt, K Hugo, M Gutierrez, RR Bowsher, ... Diabetes care 22 (9), 1422-1427, 1999 | 330 | 1999 |
| The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes JP Frias, EJ Bastyr, L Vignati, MH Tschoep, C Schmitt, K Owen, ... Cell Metabolism 26 (2), 343-352. e2, 2017 | 282 | 2017 |
| The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy EJ Vinik, RP Hayes, A Oglesby, E Bastyr, P Barlow, SL Ford-Molvik, ... Diabetes technology & therapeutics 7 (3), 497-508, 2005 | 271 | 2005 |
| Development and validity testing of the neuropathy total symptom score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy EJ Bastyr III, KL Price, V Bril, MBBQ Study Group Clinical therapeutics 27 (8), 1278-1294, 2005 | 233 | 2005 |
| Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C β-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double … AI Vinik, V Bril, P Kempler, WJ Litchy, S Tesfaye, KL Price, EJ Bastyr III, ... Clinical therapeutics 27 (8), 1164-1180, 2005 | 219 | 2005 |
| A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-β inhibitor ruboxistaurin on skin microvascular blood flow and … CM Casellini, PM Barlow, AL Rice, M Casey, K Simmons, G Pittenger, ... Diabetes care 30 (4), 896-902, 2007 | 166 | 2007 |
| Challenges in design of multicenter trials: end points assessed longitudinally for change and monotonicity PJ Dyck, JE Norell, H Tritschler, K Schuette, R Samigullin, D Ziegler, ... Diabetes care 30 (10), 2619-2625, 2007 | 137 | 2007 |
| Corrected QT interval prolongation as diagnostic tool for assessment of cardiac autonomic neuropathy in diabetes mellitus JM Gonin, MM Kadrofske, S Schmaltz, EJ Bastyr III, AI Vinik Diabetes Care 13 (1), 68-71, 1990 | 104 | 1990 |
| Platelet activity and phosphoinositide turnover increase with advancing age EJ Bastyr III, MM Kadrofske, AI Vinik The American journal of medicine 88 (6), 601-606, 1990 | 100 | 1990 |
| The effects of LY2189265, a long‐acting glucagon‐like peptide‐1 analogue, in a randomized, placebo‐controlled, double‐blind study of overweight/obese patients with type 2 … GE Umpierrez, T Blevins, J Rosenstock, C Cheng, JH Anderson, ... Diabetes, Obesity and Metabolism 13 (5), 418-425, 2011 | 96 | 2011 |
| Sural sensory action potential identifies diabetic peripheral neuropathy responders to therapy AI Vinik, V Bril, WJ Litchy, KL Price, EJ Bastyr III, MBBQ Study Group Muscle & nerve 32 (5), 619-625, 2005 | 94 | 2005 |
| Factors that impact symptomatic diabetic peripheral neuropathy in placebo-administered patients from two 1-year clinical trials S Tesfaye, R Tandan, EJ Bastyr III, KA Kles, V Skljarevski, KL Price, ... Diabetes care 30 (10), 2626-2632, 2007 | 71 | 2007 |
| Lipid and carbohydrate metabolism in IDDM during moderate and intense exercise CA Raguso, AR Coggan, A Gastaldelli, LS Sidossis, EJ Bastyr III, ... Diabetes 44 (9), 1066-1074, 1995 | 70 | 1995 |
| Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure EJ Bastyr III, ME Johnson, ME Trautmann, JH Anderson Jr, L Vignati, ... Clinical therapeutics 21 (10), 1703-1714, 1999 | 58 | 1999 |
| Diagnosis of diabetic peripheral neuropathy among patients with type 1 and type 2 diabetes in France, Italy, Spain, and the United Kingdom A Rubino, MD Rousculp, K Davis, J Wang, EJ Bastyr, S Tesfaye Primary care diabetes 1 (3), 129-134, 2007 | 55 | 2007 |
| Clinical safety of the selective PKC-β inhibitor, ruboxistaurin JB McGill, GL King, PH Berg, KL Price, KA Kles, EJ Bastyr, DL Hyslop Expert opinion on drug safety 5 (6), 835-845, 2006 | 53 | 2006 |
| 40th EASD Annual Meeting of the European Association for the Study of Diabetes: Munich, Germany, 5–9 September 2004 M Veitenhansl, K Stegner, FX Hierl, C Dieterle, H Feldmeier, B Gutt, ... Diabetologia 47, A1-A464, 2004 | 51 | 2004 |
| Randomized, double‐blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes … RM Bergenstal, H Lunt, E Franek, F Travert, J Mou, Y Qu, CJ Antalis, ... Diabetes, Obesity and Metabolism 18 (11), 1081-1088, 2016 | 50 | 2016 |
| Decreased platelet phosphoinositide turnover and enhanced platelet activation in IDDM EJ Bastyr III, MM Kadrofske, RC Dershimer, AI Vinik Diabetes 38 (9), 1097-1102, 1989 | 41 | 1989 |
